Huntsman Cancer Institute | Strategic Alliance Partners

Latest from Huntsman Cancer Institute

Hormonal Agents Improve Survival in mCSPC, but Novel Targets Are Needed For Further Drug Development

January 26, 2021

Neeraj Agarwal, MD, discusses the role of docetaxel in the frontline setting, the emergence of novel hormonal agents in the paradigm, and efforts being made with combination regimens to potentially treat patients with resistant disease.

Breast Cancer: Chaired by Christos Vaklavas, MD

January 12, 2021

Early detection, personalized treatment approaches, and increased situational awareness have improved cancer patient survival rates. Ongoing dialogue among leading experts can only improve patient outcomes and advance the field of breast cancer.